Evidence map›Paper›PMID 42479727›Full record

ArticlePloS one2026

Establishment and characterization of three canine ameloblastoma cell lines with genomic and transcriptomic profiles.

Stephanie Goldschmidt, Natalia Vapniarsky, John D McPherson, Iris Rivas, Christine Ly, Abraham Morales, Daniel York, Robert Rebhun, Maria Soltero-Rivera

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Stephanie GoldschmidtDepartment of Surgical and Radiological Services, University of California, Davis School of Veterinary Medicine, Davis California, United States of America.ORCID https://orcid.org/0000-0001-5944-4202
Natalia VapniarskyDepartment of Pathology, Microbiology, and Immunology, University of California, Davis School of Veterinary Medicine, Davis California, United States of America.ORCID https://orcid.org/0000-0003-3239-6233
John D McPhersonDepartment of Biochemistry and Molecular Medicine, University of California, Davis School of Medicine, Davis, California, United States of America.
Iris RivasDepartment of Pathology, Microbiology, and Immunology, University of California, Davis School of Veterinary Medicine, Davis California, United States of America.ORCID https://orcid.org/0000-0003-2971-0674
Christine LyDepartment of Pathology, Microbiology, and Immunology, University of California, Davis School of Veterinary Medicine, Davis California, United States of America.
Abraham MoralesDepartment of Surgical and Radiological Services, University of California, Davis School of Veterinary Medicine, Davis California, United States of America.
Daniel YorkDepartment of Surgical and Radiological Services, University of California, Davis School of Veterinary Medicine, Davis California, United States of America.
Robert RebhunDepartment of Surgical and Radiological Services, University of California, Davis School of Veterinary Medicine, Davis California, United States of America.
Maria Soltero-RiveraDepartment of Surgical and Radiological Services, University of California, Davis School of Veterinary Medicine, Davis California, United States of America.

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
UC Davis Clinical and Translational Science CenterUL1TR001860 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KENYON, NICHOLAS J., LYLES, COURTNEY REES · 2016 to 2025
$47.3M
UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development ProgramK12CA138464 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BIRKELAND, ANDREW CHARLES, LARA, PRIMO N. · 2011 to 2025
$11.4M
NCATS NIH HHS UL1 TR001860NCI NIH HHS K12 CA138464NCI NIH HHS P30 CA093373
6 · The paper itself

Abstract

Establishment of canine acanthomatous ameloblastoma (CAA) cell lines has profound importance in pre-clinical in vitro testing. The goal of this study was to develop, authenticate, and characterize three CAA cell lines. Cell lines were developed with standard cell culture techniques from dogs with naturally occurring CAA. Each cell line was authenticated as canine with a validated PCR panel. Epithelial cell origin was confirmed with pan-CK flow cytometry. Next generation DNA and RNA sequencing characterized features of the cell lines and compared them to the parent tumor. We confirmed that all cell lines maintained mutations seen in the parent tumors including a missense HRAS mutation and RTK-RAS pathway upregulation across all samples. Other common mutations (2/3 cell lines and their parent tumors) included ADGRA3, DNAH7, F10, KIAA1671, OGFR, SLC6A17, SNX7, SPTBN5, TENM4, and YEATS2. We compared the transcriptional profiles from our parent tumors and established cell lines to historical transcriptomic analysis of CAA and healthy gingiva. We confirmed the same canonical CAA molecular features of primary tumors across studies with distinct clustering from healthy gingiva. Further, we documented that the cell lines maintained upregulated genes that are seen within in vivo CAA across both studies including upregulated GPC4 and ETV5 as well as gene sets associated with the presence of epithelial-mesenchymal transformation, KRAS, Pi3K-AKT signaling, and hedgehog signaling pathways. Thorough characterization of the mutational and transcriptional profiles of the established cell lines, especially in context to how they differ from the parent tumors, sets the platform for translational in vitro testing.

Indexed as

AmeloblastomaDog DiseasesTranscriptomeAnimalsCell Line, TumorDogsGene Expression ProfilingGene Expression Regulation, NeoplasticGenomicsMutationSignal Transduction

Identifiers

PMID42479727
PMCPMC13387547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.